Cambridge biotech wins approval for first ALS drug


Amylyx Pharmaceuticals Inc. has won its first approval from the U.S. Food and Drug Administration for a drug designed to treat amyotrophic lateral sclerosis, or ALS.

Previous TBJ Fast 50 2022 — No. 45: Triad Financial Advisors
Next TBJ Fast 50 2022 — No. 23: Pacific Highway Wines & Spirits LLC